NewsDialy
The short version: Novo Nordisk may have secured an additional financial advantage from its agreement with the Trump administration to lower obesity drug costs for seniors.
This potential benefit sits on top of the existing deal.
An MFN, or most favored nation, agreement is a contract clause that requires a supplier to offer the lowest price it gives to any other buyer to all parties in the group.
What was signed versus what is only projected STAT reported previously that both Eli Lilly and Novo Nordisk benefited from their respective deals with the administration.
Keep reading